Unlocking the Potential of LOC105379648: A DLA Class II Histocompatibility Antigen as a Drug Target or Biomarker

Unlocking the Potential of LOC105379648: A DLA Class II Histocompatibility Antigen as a Drug Target or Biomarker

The immune system is a critical regulator of human health, ensuring the survival of the host against a wide range of pathogens. One of the key components of the immune system are the histocompatibility antigens (HCAbs), which are proteins that recognize and respond to foreign substances in the body. The most abundant HCAbs are the major histocompatibility complex (MHC) antigens, which are present in all tissues and cells of the body. However, there are also other HCAbs, such as the DLA class II histocompatibility antigen (LOC105379648), that have been identified and are being explored as potential drug targets or biomarkers. In this article, we will explore the potential of LOC105379648 as a drug target or biomarker.

LOC105379648: A DLA Class II Histocompatibility Antigen

LOC105379648 is a 22-kDa protein that belongs to the DLA class II histocompatibility antigen family. DLA antigens are a subset of the major histocompatibility complex (MHC) antigens and are involved in the immune response by presenting antigens to T-cells. LOC105379648 is a single gene product and is expressed in most tissues and cells of the body, including the skin, hair, nails, thymus, spleen, and various organs.

LOC105379648 functions as a histocompatibility antigen by recognizing and responding to foreign substances in the body. Specifically, LOC105379648 recognizes the major histocompatibility complex (MHC) class II molecules, which are a major source of antigens for T-cells. MHC class II molecules are responsible for presenting antigens from the body's own cells to T-cells, thereby triggering an immune response.

LOC105379648 has been shown to play a role in various physiological processes in the body, including immune surveillance, inflammation, and tissue repair. For example, LOC105379648 has been shown to be involved in the regulation of cell proliferation and differentiation, as well as in the immune response. Additionally, LOC105379648 has been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

As a Drug Target

The potential of LOC105379648 as a drug target is high due to its unique structure and the diverse functions it is involved in. One of the main advantages of LOC105379648 is its expression in most tissues, making it a potential target for small molecules that can be administered to a wide range of cells. Additionally, LOC105379648's functions in the immune system and tissue repair make it an attractive target for drugs that aim to modulate the immune response and promote tissue repair.

LOC105379648 has been shown to interact with various signaling pathways, including the T-cell signaling pathway. This suggests that LOC105379648 may be a good candidate for drugs that target this pathway, such as immunosuppressants or cytokines. Additionally, LOC105379648 has been shown to play a role in the regulation of cellular adhesion, which is a critical process in tissue repair and regeneration. Targeting LOC105379648 may therefore be a promising approach

Protein Name: DLA Class II Histocompatibility Antigen, DR-1 Beta Chain-like

The "LOC105379648 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105379648 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC105379652 | LOC105379656 | LOC105379658 | LOC105379660 | LOC105379663 | LOC105379664 | LOC105379665 | LOC105379667 | LOC105379749 | LOC105379857 | LOC105447645 | LOC107983962 | LOC107983963 | LOC107983974 | LOC107983976 | LOC107983981 | LOC107983982 | LOC107983986 | LOC107984003 | LOC107984041 | LOC107984063 | LOC107984079 | LOC107984098 | LOC107984108 | LOC107984113 | LOC107984118 | LOC107984129 | LOC107984137 | LOC107984144 | LOC107984145 | LOC107984146 | LOC107984179 | LOC107984214 | LOC107984221 | LOC107984238 | LOC107984251 | LOC107984256 | LOC107984264 | LOC107984284 | LOC107984314 | LOC107984316 | LOC107984326 | LOC107984361 | LOC107984363 | LOC107984381 | LOC107984390 | LOC107984408 | LOC107984526 | LOC107984530 | LOC107984536 | LOC107984543 | LOC107984558 | LOC107984563 | LOC107984567 | LOC107984576 | LOC107984588 | LOC107984625 | LOC107984626 | LOC107984634 | LOC107984647 | LOC107984654 | LOC107984665 | LOC107984671 | LOC107984703 | LOC107984706 | LOC107984710 | LOC107984737 | LOC107984755 | LOC107984782 | LOC107984788 | LOC107984793 | LOC107984798 | LOC107984827 | LOC107984867 | LOC107984869 | LOC107984880 | LOC107984901 | LOC107984903 | LOC107984911 | LOC107984913 | LOC107984928 | LOC107984932 | LOC107984934 | LOC107984942 | LOC107984948 | LOC107984965 | LOC107984993 | LOC107985004 | LOC107985038 | LOC107985067 | LOC107985072 | LOC107985085 | LOC107985096 | LOC107985129 | LOC107985157 | LOC107985165 | LOC107985173 | LOC107985174 | LOC107985179 | LOC107985203